CNTA Stock - Centessa Pharmaceuticals plc
Unlock GoAI Insights for CNTA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | $6.85M | N/A | N/A | N/A |
| Gross Profit | N/A | $6.85M | N/A | N/A | N/A |
| Gross Margin | N/A | 100.0% | N/A | N/A | N/A |
| Operating Income | $-201,055,000 | $-171,283,000 | $-212,263,000 | $-374,867,000 | $-10,440,000 |
| Net Income | $-235,757,000 | $-151,085,000 | $-216,207,000 | $-381,900,000 | $-10,663,000 |
| Net Margin | N/A | -2204.7% | N/A | N/A | N/A |
| EPS | $-2.06 | $-1.57 | $-2.31 | $-4.24 | $-0.08 |
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of concept stage comprising LB101, a PD-L1xCD47 LockBody, as well as LB201, a PD-L1xCD3 LockBody, which are designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874, a small molecule pharmacological chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase I clinical development for the treatment of alpha-1-antitrypsin deficiency; MGX292, a recombinant modified BMP9 replacement protein designed to overcome the deficiency in BMP9 signaling in Pulmonary Arterial Hypertension; and OX2R Agonists that are oral and intranasal selective orexin receptor 2 agonists designed to leverage structural insights and to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1. In addition, the company has exploratory pipeline products under clinical proof of concept stage containing CBS001, an anti-LIGHT antibody, which preferentially binds the inflammatory membrane form of LIGHT in inflammatory/fibrotic diseases; and CBS004, a humanized mAb specific to BDCA2, expressed exclusively on plasmacytoid dendritic cells in systemic sclerosis, systemic lupus erythematosus, and other autoimmune diseases. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 10th 2025 | Oppenheimer | Resumed | Outperform | $62 |
| October 28th 2025 | Stephens | Initiation | Overweight | $35 |
| September 3rd 2025 | Wells Fargo | Initiation | Overweight | $31 |
| August 29th 2025 | Oppenheimer | Resumed | Outperform | $40 |
| July 21st 2025 | Truist | Initiation | Buy | $30 |
| May 28th 2025 | Needham | Initiation | Buy | $35 |
| May 8th 2025 | Chardan Capital Markets | Initiation | Buy | $30 |
| March 31st 2025 | Piper Sandler | Initiation | Overweight | $38 |
| January 7th 2025 | TD Cowen | Initiation | Buy | - |
| September 20th 2024 | Morgan Stanley | Upgrade | Overweight | $26← $11 |
| September 19th 2024 | B. Riley Securities | Initiation | Buy | $33 |
| July 18th 2024 | Oppenheimer | Initiation | Outperform | $14 |
| November 15th 2023 | Jefferies | Upgrade | Buy | $11← $4 |
| October 26th 2023 | Morgan Stanley | Upgrade | Equal Weight | $8← $4 |
| June 21st 2023 | Evercore ISI | Initiation | Outperform | - |
Earnings History & Surprises
CNTAEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 23, 2026 | $-0.38 | — | — | — |
Q4 2025 | Nov 5, 2025 | $-0.39 | $-0.41 | -5.1% | ✗ MISS |
Q3 2025 | Aug 12, 2025 | $-0.35 | $-0.38 | -8.6% | ✗ MISS |
Q2 2025 | May 14, 2025 | $-0.35 | $-0.20 | +42.9% | ✓ BEAT |
Q1 2025 | Mar 24, 2025 | $-0.38 | $-0.34 | +10.5% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.42 | $-0.37 | +11.9% | ✓ BEAT |
Q3 2024 | Aug 13, 2024 | $-0.38 | $-0.40 | -5.3% | ✗ MISS |
Q2 2024 | May 13, 2024 | $-0.41 | $-0.38 | +7.3% | ✓ BEAT |
Q1 2024 | Mar 28, 2024 | $-0.44 | $-0.38 | +13.6% | ✓ BEAT |
Q4 2023 | Nov 13, 2023 | $-0.46 | $-0.40 | +13.0% | ✓ BEAT |
Q3 2023 | Aug 14, 2023 | $-0.43 | $-0.26 | +39.5% | ✓ BEAT |
Q2 2023 | May 12, 2023 | $-0.41 | $-0.53 | -29.3% | ✗ MISS |
Q1 2023 | Mar 30, 2023 | $-0.48 | $-0.45 | +6.2% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-0.49 | $-0.57 | -16.3% | ✗ MISS |
Q3 2022 | Aug 10, 2022 | $-0.56 | $-0.69 | -23.2% | ✗ MISS |
Q2 2022 | May 16, 2022 | $-0.70 | $-0.60 | +14.3% | ✓ BEAT |
Q1 2022 | Mar 30, 2022 | $-0.60 | $-0.68 | -13.3% | ✗ MISS |
Q4 2021 | Nov 15, 2021 | $-0.55 | $-0.45 | +18.2% | ✓ BEAT |
Q3 2021 | Aug 16, 2021 | $-0.73 | $-0.65 | +11.0% | ✓ BEAT |
Q2 2021 | Jun 1, 2021 | — | $-2.75 | — | — |
Latest News
Centessa Pharmaceuticals Names Orexin Program Founder Mario Accardi As Chief Executive Officer Effective January 1 2026 As Company Advances OX2R Agonist Pipeline Including ORX750 Toward Q1 2026 Registrational Program
📈 PositiveOppenheimer Maintains Outperform on Centessa Pharmaceuticals, Raises Price Target to $62
📈 PositiveB. Riley Securities Maintains Buy on Centessa Pharmaceuticals, Raises Price Target to $42
📈 PositiveGuggenheim Maintains Buy on Centessa Pharmaceuticals, Raises Price Target to $43
📈 PositiveWells Fargo Maintains Overweight on Centessa Pharmaceuticals, Raises Price Target to $35
📈 PositiveCentessa Pharmaceuticals shares are trading higher. The company announced the pricing of a $250 million public offering of American depositary shares.
📈 PositiveReported Earlier, Centessa Pharmaceuticals Prices $250M Public Offering Of 11,627,907 American Depositary Shares At $21.50 Per Share
➖ NeutralCentessa Pharmaceuticals Announces Underwritten Offering Of American Depositary Shares; Terms Not Disclosed
➖ NeutralWells Fargo Maintains Overweight on Centessa Pharmaceuticals, Lowers Price Target to $30
➖ NeutralCentessa Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q3 EPS results
📉 NegativeCentessa Pharmaceuticals' Phase 2a Data1 From Initial Dosing Groups Demonstrates OX2R Agonist Addressing Wakefulness Needs Throughout NT1 Participants; ORX750 Generally Well-Tolerated
📈 PositiveCentessa Pharmaceuticals Q3 EPS $(0.41) Misses $(0.39) Estimate
📉 NegativeStephens & Co. Initiates Coverage On Centessa Pharmaceuticals with Overweight Rating, Announces Price Target of $35
📈 PositiveGuggenheim Reiterates Buy on Centessa Pharmaceuticals, Maintains $28 Price Target
📈 PositiveCentessa Pharmaceuticals shares are trading higher. Truist Financial maintains its buy rating on the stock.
📈 PositiveWells Fargo Initiates Coverage On Centessa Pharmaceuticals with Overweight Rating, Announces Price Target of $31
📈 PositiveFrequently Asked Questions about CNTA
What is CNTA's current stock price?
What is the analyst price target for CNTA?
What sector is Centessa Pharmaceuticals plc in?
What is CNTA's market cap?
Does CNTA pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to CNTA for comparison